Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Efficacy and Safety Evaluation of Asenapine (10-20 mg/Day) in With Schizophrenia or Schizoaffective Disorder, in a Multicenter Trial Using (10-20 mg/Day) as a Control

NCT00212771 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT00212771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00212771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Efficacy and Safety Evaluation of Asenapine (10-20 mg/Day) in With Schizophrenia or Schizoaffective Disorder, in a Multicenter Trial Using (10-20 mg/Day) as a Control
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
October 31, 2006
Enrollment
440 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia